Arrowhead Pharmaceuticals Newsroom

2024's 'Biggest Loses' That Could See Reversal in 2025

Seeking AlphaDec 23 23:00

Express News | Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of Aro-Inhbe for the Treatment of Obesity

BreakingsDec 23 20:30

Arrowhead Pharmaceuticals Insider Sold Shares Worth $567,486, According to a Recent SEC Filing

MT NewswiresDec 23 17:03

H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $80

Futu NewsDec 21 03:31 · Ratings

Arrowhead Pharmaceuticals Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow JonesDec 21 00:12 · Ratings

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BusinesswireDec 20 05:59

Express News | Arrowhead Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BreakingsDec 20 05:59

Leadership Transition at Arrowhead Pharmaceuticals' Board

TipRanksDec 18 19:34

In the Wake of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Latest US$112m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions

Simply Wall StDec 18 01:16

B.Riley Financial Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Announces Target Price $51

Futu NewsDec 12 21:31 · Ratings

B. Riley Lowers Price Target on Arrowhead Pharmaceuticals to $51 From $55, Keeps Buy Rating

MT NewswiresDec 12 20:54 · Ratings

Arrowhead Pharmaceuticals: Positioned for Growth With Strategic Partnerships and SiRNA Advancements

TipRanksDec 12 20:35

Chardan Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $60

Futu NewsDec 12 10:31 · Ratings

Promising Clinical Trial Results Boost Confidence in Arrowhead Pharmaceuticals, Justifying Buy Rating

TipRanksDec 12 10:15 · Ratings

Arrowhead Pharmaceuticals Announced Interim Results From A Phase 1/2A Clinical Study Of ARO-CFB, The Company's Investigational RNA Interference (RNAi) Therapeutic Targeting Complement Factor B Being Developed As A Potential Treatment For Complement...

BenzingaDec 11 20:40

Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) Have Lost 66%, as Stock Drops 9.3% This Past Week

Yahoo FinanceDec 7 22:31

Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $45

Futu NewsDec 6 00:35 · Ratings

Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Arrowhead Pharmaceuticals (ARWR) and Heron Therapeutics (HRTX)

TipRanksDec 6 00:10 · Ratings

Arrowhead Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow JonesDec 4 01:17 · Ratings

Arrowhead Pharmaceuticals Price Target Raised to $80.00/Share From $60.00 by HC Wainwright & Co.

Dow JonesDec 4 01:17 · Ratings